PCLX-001

Cat. No.:	HY-147308
CAS No.:	1215011-08-7
Molecular Formula:	$C_{24}H_{30}Cl_2N_6O_2S$
Molecular Weight:	537.51
Target:	Others
Pathway:	Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (18.60 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8604 mL	9.3022 mL	18.6043 mL
	5 mM	0.3721 mL	1.8604 mL	3.7209 mL
	10 mM	0.1860 mL	0.9302 mL	1.8604 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1 mg/mL (1.86 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1 mg/mL (1.86 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1 mg/mL (1.86 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PCLX-001 is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC_{50}s of 5 nM (NMT1) and 8 nM (NMT2), respectively. PCLX-001 exhibits anti-tumor activity and inhibits early B-cell receptor (BCR) signaling, can be used to B-cell malignancies research[1][2].

REFERENCES

[1]. Michael Weickert, et al. Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies. Blood. 2019. 134(s1):3362.

[2]. Beauchamp E, et al. Targeting N-myristoylation for therapy of B-cell lymphomas. Nat Commun. 2020 Oct 22;11(1):5348.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA